Published in Cancer Invest on April 01, 2003
Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther (2009) 1.05
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther (2010) 0.80
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
In vivo magnetic resonance imaging of transgene expression. Nat Med (2000) 3.35
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 2.13
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif (2001) 1.86
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 1.60
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ (2009) 1.27
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol (1998) 1.14
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Cellular automaton of idealized brain tumor growth dynamics. Biosystems (2000) 1.10
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci (1990) 1.06
Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg (2000) 1.06
Emergence of a subpopulation in a computational model of tumor growth. J Theor Biol (2000) 1.06
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther (1998) 1.04
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther (1994) 1.03
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol (1995) 1.03
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther (1994) 1.02
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther (1996) 1.02
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther (1995) 1.01
Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol (2000) 1.00
Gene therapy for brain tumors. Brain Pathol (1995) 1.00
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 1.00
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg (1999) 0.99
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther (1994) 0.98
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 0.97
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther (2004) 0.95
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg (1998) 0.95
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res (2001) 0.95
The subtemporal-transpetrous approach for excision of petroclival tumors. Am J Otol (1996) 0.94
Genetic strategies for brain tumor therapy. Cancer Gene Ther (2006) 0.92
Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg (2000) 0.92
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res (2000) 0.92
Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res (1995) 0.91
Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery (1999) 0.91
Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol (1998) 0.88
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol (1992) 0.87
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res (2001) 0.86
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther (1999) 0.86
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther (1996) 0.85
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res (1997) 0.85
Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther (1995) 0.85
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther (2006) 0.85
Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res (1993) 0.85
A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol (1998) 0.84
Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs (2000) 0.84
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther (2000) 0.84
Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther (1999) 0.84
Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther (1995) 0.83
Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther (2012) 0.82
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther (2013) 0.82
Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg (1990) 0.81
Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet (2000) 0.80
Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. J Neurovirol (1998) 0.80
Petroclival meningioma presenting with pathological laughter. Neurology (1998) 0.80
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther (1998) 0.79
A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther (1996) 0.79
Transglutaminases and their regulation: implications for polyamine metabolism. Adv Exp Med Biol (1988) 0.79
Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Ther (2003) 0.79
Multicolumn infusion of gene therapy cells into human brain tumors: technical report. Neurosurgery (2000) 0.78
Gene therapy for tumors of the central nervous system. Surg Oncol Clin N Am (1998) 0.78
Family history of cancer in benign brain tumor subtypes versus gliomas. Front Oncol (2012) 0.77
Retinoid--regulated expression of tissue transglutaminase in normal and leukemic myeloid cells. Adv Exp Med Biol (1988) 0.77
Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain. Gene Ther (2012) 0.77
Retinoids as generalized regulators of cellular growth and differentiation. Am J Med Sci (1988) 0.77
Neurogenetic surgery: current limitations and the promise of gene- and virus-based therapies. Clin Neurosurg (1999) 0.77
Regression of experimental brain tumors with 6-thioxanthine and Escherichia coli gpt gene therapy. Hum Gene Ther (1997) 0.76
Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther (1996) 0.76
Growth of human schwannomas in the subrenal capsule of the nude mouse. Neurosurgery (1990) 0.76
Nerve growth factor protects against herpes simplex virus type 1 neurotoxicity in the rat striatum. Neuroreport (1994) 0.75
Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res (1998) 0.75
Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Front Radiat Ther Oncol (1999) 0.75
[Herpes simplex type-1 virus-based vectors for gene therapy]. Nihon Rinsho (2000) 0.75
[Gene therapy for brain tumors: gene therapy for malignant brain tumors using prodrug-sensitivity genes (series 4)]. No Shinkei Geka (1994) 0.75
A simple method of eluting proteins from two-dimensional gels. Clin Chem (1982) 0.75
Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. J Gastrointest Surg (2000) 0.75
A review of gene therapy for the treatment of central nervous system tumors. Crit Rev Oncog (1999) 0.75